Linezolid and the risk of QT interval prolongation: A pharmacovigilance study of the Food and Drug Administration Adverse Event Reporting System.

Shao, Haixia; Shi, Dawei; Dai, Ying

Shao, Haixia; Shi, Dawei; Dai, Ying.

Afiliação

Shao H; Department of Pharmacy, Second Affiliated Hospital and Yuying Children's hospital of Wenzhou Medical University, Wenzhou City, China.
Shi D; Department of Pharmacy, First Affiliated Hospital of Wenzhou Medical University, Wenzhou City, China.
Dai Y; Department of Pharmacy, First Affiliated Hospital of Wenzhou Medical University, Wenzhou City, China.

Br J Clin Pharmacol ; 89(4): 1386-1392, 2023 04.

Article em En | MEDLINE | ID: mdl-36346345

Assuntos

Síndrome do QT Longo; Torsades de Pointes; Estados Unidos/epidemiologia; Humanos; Linezolida/efeitos adversos; Farmacovigilância; United States Food and Drug Administration; Síndrome do QT Longo/induzido quimicamente; Síndrome do QT Longo/epidemiologia

Palavras-chave

QT interval prolongation; cardiotoxicity; linezolid; long QT syndrome; pharmacovigilance; torsade de pointes

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Síndrome do QT Longo / Torsades de Pointes Tipo de estudo: Etiology_studies / Risk_factors_studies Limite: Humans País/Região como assunto: America do norte Idioma: En Revista: Br J Clin Pharmacol Ano de publicação: 2023 Tipo de documento: Article País de afiliação: China

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google